Pfizer settles Impax patent lawsuit over sale of generic Detrol LA
World’s largest pharmaceutical company Pfizer Inc has settled a patent lawsuit over the application by Impax Laboratories Inc to sell the copy of the bladder-control treatment Detrol LA.
The terms of the accord were not completely disclosed in the filing yesterday in the federal court in Newark, New Jersey, referring to the license deal dated Aug 16 between the 2 companies, the news reports said.
Pfizer sued Impax in 2008, claiming that it infringed the three patents in applying for U.S. Food and Drug Administration approval to copy its extended-release capsules.
The settlement prohibits Impax from selling any generic version of the drug during the life of the two of the patents except as permitted under the settlement and license agreement between the companies.
Detrol LA and Detrol generated $883 million in the global sales last year for Pfizer, including the $557 million in the U.S.
Pfizer, Inc is an American multinational pharmaceutical company based in New York that develops and produces medicines and vaccines for conditions including the areas of immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain. It has its research headquarters in Groton, Connecticut and U.S.